Superluminal Medicines

Superluminal Medicines is a Boston-based biotechnology company founded in 2022 that combines artificial intelligence, protein dynamics, and structural biology to rapidly discover drugs targeting G protein-coupled receptors (GPCRs). GPCRs represent one of the largest and most important drug target classes, with approximately 35% of all FDA-approved drugs targeting these receptors, yet 70% of the 800+ GPCRs remain undruggable.

The company launched with a $33 million seed round in 2023 and closed a $120 million Series A in September 2024, led by RA Capital Management with participation from Insight Partners, NVIDIA's NVentures, and Eli Lilly. This brought total funding to approximately $158 million.

In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases. This deal validates Superluminal's AI-driven platform and positions the company at the forefront of the exploding weight loss drug market.

Superluminal's lead internal program targets the melanocortin 4 receptor (MC4R) for obesity treatment. The company announced in July 2025 that a selective, biased MC4R agonist is advancing to IND-enabling studies, with human trials expected by Q4 2026.